Présentation de l'entreprise
Becton, Dickinson and Company is a leading global manufacturer that develops, produces, and sells essential medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry participants, and the general public worldwide. Operating within the Healthcare sector and specifically the Medical Instruments & Supplies industry, the company provides critical infrastructure for patient care and medical research, positioning itself as a fundamental utility-like asset within the broader healthcare ecosystem. The organization employs approximately 70,000 individuals across its global operations, reflecting a substantial physical footprint and workforce dedication to medical innovation and distribution. With a market capitalization of $56.91 billion and annual revenue reaching $21.92 billion, the company demonstrates significant scale and liquidity in its sector. These valuation and revenue figures indicate that BDX commands a premium position as a large-cap entity, suggesting stability and a dominant market share that allows it to weather economic fluctuations better than smaller peers in the medical device industry.
Santé financière
The company generated $21.92 billion in revenue over the trailing twelve months, resulting in a net income of $1.76 billion and an EBITDA of $6.04 billion, highlighting a substantial difference between top-line sales and bottom-line profit that reveals a heavy cost structure involving manufacturing, distribution, and research expenses. After deducting interest, taxes, depreciation, and amortization, the EBITDA of $6.04 billion serves as a robust indicator of operational cash generation before non-cash charges, while the net income of $1.76 billion reflects the rigorous tax and interest obligations inherent to a firm with $19.54 billion in debt. The free cash flow stands at $3.11 billion, which signifies strong financial flexibility enabling the company to fund capital expenditures, service its debt obligations, and potentially pursue strategic acquisitions without relying on external equity financing. Margin analysis shows a gross margin of 46.8%, indicating efficient production and pricing power, an operating margin of 13.3% that reflects effective management of overhead and administrative costs, and a profit margin of 8.0% that captures the final profitability after all expenses and taxes. In terms of leverage, the company holds $751.00 million in cash against $19.54 billion in debt, resulting in a debt-to-equity ratio of 77.28%, which suggests a highly leveraged balance sheet typical of capital-intensive manufacturing but requiring careful interest rate management. The current ratio of 1.05 indicates that current assets slightly exceed current liabilities, signaling tight but manageable short-term liquidity that requires precise working capital management to meet immediate obligations. Furthermore, the return on equity of 7.0% and return on assets of 4.1% reveal the efficiency with which management utilizes shareholder capital and total assets to generate profits, with the lower ROA relative to ROE reflecting the impact of the high debt load on the overall return metric.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is 25.63, while the forward P/E is 11.63, implying that the market expects a significant acceleration in earnings growth or a temporary distortion in current earnings that will normalize in the future, as the forward multiple is less than half of the trailing multiple. The price-to-book ratio stands at 1.77, indicating that the market values the company at a 77% premium over its book value, which suggests investors are pricing in intangible assets, brand strength, or future growth potential beyond the tangible asset base. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 2.60 and an EV/EBITDA of 10.51, suggesting that the stock is priced at a moderate multiple relative to its sales and earnings power before interest, taxes, depreciation, and amortization. Price action over the past year shows a 52-week high of $187.35 and a 52-week low of $127.59, placing the current trading range within a wide band that reflects high volatility or a period of consolidation depending on the specific entry point relative to these extremes. The beta of 0.35 indicates that the stock exhibits low volatility relative to the broader market, moving less than one-third as much as the market index, which makes it an attractive component for risk-averse portfolios seeking stability during periods of market turbulence.
Growth & Income
Revenue growth stands at 1.6% year-over-year, while earnings growth reaches 28.6% year-over-year, demonstrating that earnings are expanding significantly faster than revenue, which typically implies an improvement in operating leverage, cost controls, or a shift in product mix toward higher-margin offerings. As a dividend payer, the company offers a yield of 2.7% with a payout ratio of 68.1%, a level that is generally sustainable given the strong free cash flow generation, though the high payout ratio leaves limited room for error if earnings growth decelerates in the coming quarters. The disparity between the modest revenue expansion and robust earnings growth highlights the company's ability to enhance profitability even when top-line volume increases are incremental, a hallmark of mature medical device companies with pricing power. Overall, the growth and income profile combines steady, albeit slow, revenue expansion with accelerating profitability and a consistent dividend yield, positioning the asset for investors seeking both capital appreciation potential and income stability within the defensive healthcare sector.